Loading...

Dermira

DB:19D
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
19D
DB
$534M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
  • Dermira has significant price volatility in the past 3 months.
19D Share Price and Events
7 Day Returns
43.4%
DB:19D
0.8%
DE Pharmaceuticals
1.3%
DE Market
1 Year Returns
51.1%
DB:19D
-11.3%
DE Pharmaceuticals
-7.6%
DE Market
19D Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dermira (19D) 43.4% 55.6% 32.2% 51.1% - -
DE Pharmaceuticals 0.8% 1.7% 6.6% -11.3% -13.8% 18%
DE Market 1.3% 2.8% 7.5% -7.6% 9.3% 13.3%
1 Year Return vs Industry and Market
  • 19D outperformed the Pharmaceuticals industry which returned -11.3% over the past year.
  • 19D outperformed the Market in Germany which returned -7.6% over the past year.
Price Volatility
19D
Industry
5yr Volatility vs Market

19D Value

 Is Dermira undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Dermira is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Dermira has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Dermira. This is due to cash flow or dividend data being unavailable. The share price is €10.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dermira's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dermira's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:19D PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-5.27
NasdaqGS:DERM Share Price ** NasdaqGS (2019-03-19) in USD $14.13
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 28.06x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 19.26x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dermira.

DB:19D PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:DERM Share Price ÷ EPS (both in USD)

= 14.13 ÷ -5.27

-2.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dermira is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • Dermira is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Dermira's expected growth come at a high price?
Raw Data
DB:19D PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
19.7%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.84x
Germany Market PEG Ratio Median Figure of 276 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Dermira, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Dermira's assets?
Raw Data
DB:19D PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.21
NasdaqGS:DERM Share Price * NasdaqGS (2019-03-19) in USD $14.13
Germany Pharmaceuticals Industry PB Ratio Median Figure of 10 Publicly-Listed Pharmaceuticals Companies 2.18x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.76x
DB:19D PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:DERM Share Price ÷ Book Value per Share (both in USD)

= 14.13 ÷ -0.21

-66.17x

* Primary Listing of Dermira.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dermira has negative assets, we can't compare the value of its assets to the DE Pharmaceuticals industry average.

Next steps:

  1. Examine Dermira's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Dermira's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Dermira's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Dermira has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

19D Future Performance

 How is Dermira expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dermira expected to grow at an attractive rate?
  • Unable to compare Dermira's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Dermira's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Dermira's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:19D Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:19D Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 19.7%
DB:19D Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 42.3%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.3%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:19D Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:19D Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 330 55 -15 7
2022-12-31 208 -117 -138 7
2021-12-31 132 -186 -201 7
2020-12-31 72 -214 -250 8
2019-12-31 24 -191 -258 5
DB:19D Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 42 -213 -222
2018-09-30 41 -166 -206
2018-06-30 42 -142 -318
2018-03-31 4 -134 -333
2017-12-31 5 -104 -303
2017-09-30 26 -72 -255
2017-06-30 25 -60 -101
2017-03-31 24 -73 -90
2016-12-31 23 -74 -89
2016-09-30 0 -89 -113
2016-06-30 7 -83 -103
2016-03-31 7 -69 -93

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Dermira is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Dermira's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:19D Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Dermira Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:19D Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.64 0.18 -2.05 6.00
2022-12-31 -2.29 -1.20 -3.85 6.00
2021-12-31 -3.50 -2.70 -5.11 6.00
2020-12-31 -4.96 -3.83 -6.96 7.00
2019-12-31 -5.65 -4.28 -7.07 7.00
DB:19D Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -5.27
2018-09-30 -4.91
2018-06-30 -7.62
2018-03-31 -7.99
2017-12-31 -7.48
2017-09-30 -6.52
2017-06-30 -2.69
2017-03-31 -2.59
2016-12-31 -2.70
2016-09-30 -3.57
2016-06-30 -3.49
2016-03-31 -3.31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Dermira will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Dermira's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dermira has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

19D Past Performance

  How has Dermira performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dermira's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dermira does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Dermira's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Dermira's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Dermira's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dermira Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:19D Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 42.34 -221.54 172.58 43.37
2018-09-30 41.44 -205.74 148.03 44.76
2018-06-30 41.79 -318.37 118.27 45.25
2018-03-31 3.77 -333.01 91.09 40.73
2017-12-31 4.54 -303.26 71.90 35.76
2017-09-30 25.66 -254.63 54.16 32.16
2017-06-30 24.72 -100.97 42.68 30.11
2017-03-31 23.65 -90.16 35.47 27.48
2016-12-31 22.59 -89.08 30.04 24.99
2016-09-30 0.12 -112.85 25.59 23.00
2016-06-30 7.30 -103.40 22.00 19.42
2016-03-31 7.30 -92.80 19.48 16.94
2015-12-31 7.30 -78.40 17.72 15.06
2015-09-30 14.60 -53.98 15.73 12.70
2015-06-30 7.30 -45.77 12.73 17.10
2015-03-31 7.30 -37.37 10.62 11.15
2014-12-31 7.30 -31.88 8.29 11.50
2014-09-30 -31.86 6.39 0.50
2014-06-30 -28.68 5.71 -4.24
2014-03-31 -24.76 4.94 2.40
2013-12-31 -22.35 4.37 10.94
2012-12-31 -20.25 3.15 3.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Dermira has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Dermira has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Dermira improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Dermira's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dermira has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

19D Health

 How is Dermira's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dermira's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dermira is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Dermira's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dermira's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Dermira has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dermira Company Filings, last reported 2 months ago.

DB:19D Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -9.04 313.79 313.04
2018-09-30 53.85 280.76 378.90
2018-06-30 112.45 280.31 436.93
2018-03-31 127.87 279.85 495.79
2017-12-31 149.65 279.39 550.99
2017-09-30 198.73 278.94 662.88
2017-06-30 372.41 278.47 690.76
2017-03-31 405.10 0.00 414.63
2016-12-31 247.37 0.00 251.94
2016-09-30 250.87 0.00 241.92
2016-06-30 270.92 0.00 297.86
2016-03-31 159.87 0.00 189.30
2015-12-31 185.48 0.00 214.69
2015-09-30 214.76 1.95 215.02
2015-06-30 125.20 1.94 120.41
2015-03-31 140.86 1.94 122.48
2014-12-31 153.58 1.94 97.15
2014-09-30 39.10 1.94 50.85
2014-06-30 46.67 1.93 58.59
2014-03-31 1.38 1.93 14.55
2013-12-31 9.79 1.92 22.14
2012-12-31 7.34 0.00 7.87
  • Dermira has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Dermira's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Dermira has sufficient cash runway for 1.2 years based on current free cash flow.
  • Dermira has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 57.5% each year.
X
Financial health checks
We assess Dermira's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dermira has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

19D Dividends

 What is Dermira's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Dermira dividends. Estimated to be 0% next year.
If you bought €2,000 of Dermira shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Dermira's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Dermira's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:19D Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:19D Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Dermira has not reported any payouts.
  • Unable to verify if Dermira's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Dermira's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Dermira has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Dermira's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Dermira's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dermira afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dermira has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

19D Management

 What is the CEO of Dermira's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tom Wiggans
COMPENSATION $5,805,720
AGE 66
TENURE AS CEO 8.6 years
CEO Bio

Mr. Thomas G. Wiggans, also known as Tom, co-founded Dermira, Inc. in August 2010 and has been its Chief Executive Officer since August 2010. Mr. Wiggans serves as an Advisor at Stiefel Laboratories. He has nearly 30 years of experience from the pharmaceutical and biotechnology industries. He served as the Chief Executive Officer of Peplin Inc. since August 15, 2008. He served as the Chief Executive Officer of Connetics Corporation from July 1994 to December 2006 and also served as its President from July 1994 to February 16, 2005. From February 1992 to April 1994, he served as the President and Chief Operating Officer at CytoTherapeutics Inc. From 1980 to February 1992, he served in various positions at Ares-Serono Group, including President of its U.S. Pharmaceutical Operations and Managing Director of Ares-Serono Group's U.K. Pharmaceutical Operations. From 1976 to 1980, Mr. Wiggans served various sales and marketing positions with Eli Lilly & Co. Prior to Connetics, he spent twelve years with the Ares-Serono Group in various management positions including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans serves as the Chairman of Excaliard Pharmaceuticals, Inc. He has been the Chairman of Dermira, Inc. since April 2014. He serves as the Chairman of Biotechnology Institute, The. He served as the Chairman of Connetics Corporation from January 1, 2006 to December 2006. He served as the Chairman and Director of Peplin Inc. (alternate name, Peplin Limited) since October 2007. Mr. Wiggans serves as a Director of CellExSys, Inc. He has been an Independent Director of Annexon Biosciences, Inc. since March 9, 2017. He has been a Director of Dermira, Inc. since August 2010. He serves on the Board of Overseers of the Hoover Institution at Stanford University. He serves as a Trustee of the University of Kansas Endowment Association. He served as Director of Neothetics, Inc. (alternate name, Lithera, Inc.) from April 2011 to September 10, 2014 and Onyx Pharmaceuticals, Inc. from March 10, 2005 to 2013. He served as a Director of Sangamo Therapeutics, Inc. (alternate name, Sangamo Biosciences Inc.) from June 2008 to June 21, 2012 and Pernix Sleep, Inc. (alternate name, Somaxon Pharmaceuticals Inc.) from June 2008 to June 2012. He served as a Director of Victory Pharma, Inc. and Corthera Inc. Mr. Wiggans served as a Director of Biotechnology Innovation Organization (alternate name, Biotechnology Industry Organization). He served as a Director of Abgenix Inc. since April 2003. He served as a Director of Progen Pharmaceuticals, Inc. He served as a Director of Ipsen Biopharmaceuticals, Inc. (alternate name, Tercica Inc.) from April 19, 2005 to October 13, 2006, He served as a Director of Connetics Corporation from July 1994 to December 2006. Mr. Wiggans received a BS Degree in Pharmacy from the University of Kansas and an MBA Degree from Southern Methodist University.

CEO Compensation
  • Tom's compensation has increased whilst company is loss making.
  • Tom's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Dermira management team in years:

4.6
Average Tenure
52
Average Age
  • The tenure for the Dermira management team is about average.
Management Team

Tom Wiggans

TITLE
Co-Founder
COMPENSATION
$6M
AGE
66
TENURE
8.6 yrs

Gene Bauer

TITLE
Co-Founder
COMPENSATION
$2M
AGE
76
TENURE
8.6 yrs

Andrew Guggenhime

TITLE
Chief Financial Officer
COMPENSATION
$3M
AGE
50
TENURE
4.9 yrs

Luis Peña

TITLE
Chief Development Officer
COMPENSATION
$2M
AGE
55
TENURE
3.1 yrs

Lori Lyons-Williams

TITLE
Chief Commercial Officer
COMPENSATION
$3M
AGE
41
TENURE
2.3 yrs

Chris Griffith

TITLE
Co-Founder and Chief Business & Strategy Officer
COMPENSATION
$833K
AGE
42
TENURE
8.6 yrs

Chris Horan

TITLE
Chief Technical Operations Officer
AGE
52
TENURE
0.9 yrs

Ian Clements

TITLE
Vice President of Investor Relations
TENURE
1.8 yrs

Christine Ring

TITLE
Vice President for Legal
TENURE
4.6 yrs

Erica Jefferson

TITLE
Vice President of Corporate Communications
Board of Directors Tenure

Average tenure and age of the Dermira board of directors in years:

4.9
Average Tenure
59.5
Average Age
  • The tenure for the Dermira board of directors is about average.
Board of Directors

Gene Bauer

TITLE
Co-Founder
COMPENSATION
$2M
AGE
76
TENURE
8.6 yrs

Fred Craves

TITLE
Lead Independent Director
COMPENSATION
$259K
AGE
72

Tom Wiggans

TITLE
Co-Founder
COMPENSATION
$6M
AGE
66
TENURE
4.9 yrs

Jake Nunn

TITLE
Non-Employee Director
COMPENSATION
$234K
AGE
48
TENURE
7.8 yrs

David Cohen

TITLE
Non-Employee Director
COMPENSATION
$249K
AGE
53
TENURE
4.8 yrs

Matt Fust

TITLE
Non-Employee Director
COMPENSATION
$248K
AGE
53
TENURE
4.9 yrs

Brian Berman

TITLE
Scientific Advisor

Sewon Kang

TITLE
Scientific Advisor

Howard Maibach

TITLE
Scientific Advisor

Seth Orlow

TITLE
Scientific Advisor
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Dermira's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dermira has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

19D News

Simply Wall St News

19D Company Info

Description

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

Details
Name: Dermira, Inc.
19D
Exchange: DB
Founded: 2010
$470,240,961
42,328,167
Website: http://www.dermira.com
Address: Dermira, Inc.
275 Middlefield Road,
Suite 150,
Menlo Park,
California, 94025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS DERM Common Shares Nasdaq Global Select US USD 03. Oct 2014
DB 19D Common Shares Deutsche Boerse AG DE EUR 03. Oct 2014
Number of employees
Current staff
Staff numbers
333
Dermira employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/19 21:59
End of day share price update: 2019/03/19 00:00
Last estimates confirmation: 2019/03/19
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.